Protagonist Therapeutics Inc Stock
There is an upward development for Protagonist Therapeutics Inc compared to yesterday, with an increase of €1.00 (1.360%).
With 25 Buy predictions and 1 Sell predictions Protagonist Therapeutics Inc is one of the favorites of our community.
However, we have a potential of -4.7% for Protagonist Therapeutics Inc as the target price of 71 € is below the current price of 74.5 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Protagonist Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Arturo Molina, Chief Medical Officer of Protagonist Therapeutics (NASDAQ:PTGX), directly sold 9,514 shares in an open-market transaction on Jan. 20, 2026, for an approximate value of $784,700